



## **FOR IMMEDIATE RELEASE**

Tokyo, November 18, 2022

### **JT's License Partner JW Pharmaceutical Announced that Enarodustat, a HIF-PH Inhibitor, Received Regulatory Approval in the Republic of Korea**

Japan Tobacco Inc. (JT) (TSE:2914) announced today that JW Pharmaceutical Corporation (JWP) issued a statement that ENAROY<sup>®</sup> tablets (generic name: enarodustat), a hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor, was approved by Ministry of Food and Drug Safety of the Republic of Korea for the treatment of anemia in chronic kidney disease (CKD) patients on hemodialysis on November 17, 2022.

JT out-licensed enarodustat to JWP on October 14, 2016, in accordance with the exclusive license agreement for the development and commercialization of an oral drug for the treatment of anemia associated with CKD in the Republic of Korea.

In 2020, enarodustat, discovered and developed by JT, was approved and launched for the treatment of anemia associated with CKD in Japan.

JT expects ENAROY<sup>®</sup> tablets to be a new therapeutic option for anemia in CKD patients on hemodialysis in the Republic of Korea.

#### **About Enarodustat**

Enarodustat is an orally active HIF-PH inhibitor that promotes erythropoiesis by accelerating the endogenous production of erythropoietin (EPO) and controlling the expression of molecules responsible for iron metabolism.

#### **About Anemia Associated with CKD**

Anemia is one of the complications in CKD patients. The major cause of anemia in patients with CKD is considered to be a decreased ability to produce EPO in the kidney associated with renal dysfunction. Insufficient oxygen supply due to decreased erythrocyte counts associated with anemia decreases the energy production in organs and induces reduction in mobility and activities in daily life, which leads to a poor quality of life.

###

*Japan Tobacco Inc. is a leading international tobacco company selling its products in more than 130 countries and regions. With approximately 55,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.*

Contact: Dinesh Babu Thotakura, Director  
Jo Oshiana Ogawa, Associate Manager  
Media and Investor Relations Division  
Japan Tobacco Inc.  
Tokyo: +81-3-6636-2914  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)